Bright Minds Biosciences Inc.
DRUG
CNSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.19% | 23.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.10% | 99.98% | |||
| Operating Income | 3.10% | -99.98% | |||
| Income Before Tax | -84.33% | -5,907.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -84.33% | -5,907.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -84.33% | -5,907.34% | |||
| EBIT | 3.10% | -99.98% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -83.12% | -5,224.56% | |||
| Normalized Basic EPS | -83.18% | -5,169.44% | |||
| EPS Diluted | -82.81% | -5,233.33% | |||
| Normalized Diluted EPS | -83.18% | -5,630.30% | |||
| Average Basic Shares Outstanding | 0.65% | 14.15% | |||
| Average Diluted Shares Outstanding | 0.65% | 5.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||